BLISSGVS - Bliss GVS Pharma Limited Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

BLISSGVS

40/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹460.10-9.95(-2.12%)

Market Closed as of Jun 24, 2026, 15:30 IST

Select time range

Pros

Profitability: Recent profitability of 13% is a good sign.

Technicals: Bullish SharesGuru indicator.

Balance Sheet: Strong Balance Sheet.

Past Returns: Outperforming stock! In past three years, the stock has provided 79.8% return compared to 8.8% by NIFTY 50.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: Market Cap wise it is among the top 20% companies of india.

Growth: Good revenue growth. With 31.6% growth over past three years, the company is going strong.

Momentum: Stock price has a strong positive momentum. Stock is up 69.1% in last 30 days.

Valuation
Market Cap	5.14 kCr
Price/Earnings (Trailing)	39.76
Price/Sales (Trailing)	5.08
EV/EBITDA	21.75
Price/Free Cashflow	62.82
MarketCap/EBT	27.14
Enterprise Value	5.11 kCr

Fundamentals
Revenue (TTM)	1.01 kCr
Rev. Growth (Yr)	27.7%
Earnings (TTM)	134.73 Cr
Earnings Growth (Yr)	122.2%

Profitability
Operating Margin	19%
EBT Margin	19%
Return on Equity	10.94%
Return on Assets	9.03%
Free Cashflow Yield	1.59%

Growth & Returns
Price Change 1W	11.1%
Price Change 1M	69.1%
Price Change 6M	181.3%
Price Change 1Y	258.9%
3Y Cumulative Return	79.8%
5Y Cumulative Return	35%
7Y Cumulative Return	17.8%
10Y Cumulative Return	17.8%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-38.28 Cr
Cash Flow from Operations (TTM)	138.72 Cr
Cash Flow from Financing (TTM)	-89.21 Cr
Cash & Equivalents	35.14 Cr
Free Cash Flow (TTM)	81.89 Cr
Free Cash Flow/Share (TTM)	7.74

Balance Sheet
Total Assets	1.49 kCr
Total Liabilities	260.65 Cr
Shareholder Equity	1.23 kCr
Current Assets	946.34 Cr
Current Liabilities	235.54 Cr
Net PPE	450.68 Cr
Inventory	150.73 Cr
Goodwill	7.71 Cr

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	14.79
Interest/Cashflow Ops	12.55

Dividend & Shareholder Returns
Dividend/Share (TTM)	1
Dividend Yield	0.21%
Shares Dilution (1Y)	0.40%
Shares Dilution (3Y)	1.6%

Technical Indicators
RSI (14d)	61.17
RSI (5d)	67.92
RSI (21d)	76.42
MACD Signal	Sell
Stochastic Oscillator Signal	Sell
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Hold
RSI21 Signal	Sell
SMA 5 Signal	Sell
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Shareholder Name	Holding %
NARSIMHA SHIBROOR KAMATH	30.66%
GULBARGA TRADING AND INVESTMENT PRIVATE	5.51%
ARJUN GAUTAM ASHRA	4.77%
GAUTAM RASIKLAL ASHRA	2.82%
ARIAN INVESTMENT LIMITED	2.45%
VIBHA GAGAN SHARMA	2.43%
SHRUTI VISHAL RAO	1.99%
COEUS GLOBAL OPPORTUNITIES FUND	1.76%
ARK GLOBAL EMERGING COMPANIES, LP	1.42%
QUADRATURE TRADING VCC - SUB-FUND NO. 1	1.23%
SHAILESH DALMIA	1.18%
GAGAN HARSH SHARMA	0.21%
RAMADAS VASUDEV KAMATH HUF	0.03%
PUNITA SHARMA	0.02%
SHIBROOR GOKULDAS KAMATH	0.01%
Geeta Narsimha Kamath	0%
Shibroor Ravidas Kamath	0%
Vishal Vijay Rao	0%
Shiv Kumar Sharma	0%
Radha Sharma	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.41 LCr	60.43 kCr	+1.80%	+12.80%	38.46	7.3	-	-
CIPLA	Cipla	1.16 LCr	29.04 kCr	+1.70%	-4.10%	29.93	4	-	-
LUPIN	Lupin	1.08 LCr	28.38 kCr	+3.50%	+22.60%	20.28	3.81	-	-
DRREDDY	Dr. Reddy's Lab	1.06 LCr	35.06 kCr	-0.30%	-0.70%	25.24	3.03	-	-
AUROPHARMA	Aurobindo Pharma	89.26 kCr	34.18 kCr	+5.70%	+39.20%	25.47	2.61	-	-

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	14.5%	927	810	770	752	747	577
Other Income	108.6%	74	36	29	18	31	20
Total Income	18.3%	1,001	846	799	769	779	597
Cost of Materials	3.5%	386	373	339	330	385	260
Purchases of stock-in-trade	25%	61	49	51	44	35	81
Employee Expense	21.6%	136	112	96	86	76	68
Finance costs	54.5%	12	8.12	6.91	10	4.74	5.51
Depreciation and Amortization	14.3%	33	29	26	19	17	17
Other expenses	28.8%	202	157	142	147	162	74
Total Expenses	12.2%	809	721	653	663	651	493
Profit Before exceptional items and Tax	52.8%	192	126	146	106	128	104
Exceptional items before tax	-	-2.49	0	-29.2	0	-73.59	0
Total profit before tax	51.2%	190	126	117	106	54	104
Current tax	78.9%	69	39	33	41	36	29
Deferred tax	-207.2%	-14.33	-3.99	2.03	-11.51	-4.74	1.23
Total tax	58.8%	55	35	35	29	31	30
Total profit (loss) for period	50.6%	135	90	82	77	23	74
Other comp. income net of taxes	130.7%	2.03	-2.35	4.55	-6.38	-7.41	-0.51
Total Comprehensive Income	56.3%	137	88	86	70	16	73
Earnings Per Share, Basic	60%	12.23	8.02	7.23	6.83	1.46	6.64
Earnings Per Share, Diluted	58.3%	12	7.95	7.11	6.72	1.43	6.49
Debt equity ratio	-	-	0.065	009	011	012	0
Debt service coverage ratio	-	-	0.0331	0.0396	0.0637	0.0173	0
Interest service coverage ratio	-	-	0.2693	0.2522	0.1162	-	0

Description	(%) Q/Q	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024
Revenue From Operations	18%	257	218	244	207	198	210
Other Income	-41.2%	11	18	20	35	12	15
Total Income	13.1%	268	237	265	243	210	226
Cost of Materials	29.4%	111	86	95	93	77	97
Purchases of stock-in-trade	-10.5%	18	20	2.26	21	14	19
Employee Expense	0%	36	36	33	31	28	30
Finance costs	106.1%	2.01	1.49	3.04	5.47	1.68	1.08
Depreciation and Amortization	4.4%	8.67	8.35	8.26	8.2	8.04	7.55
Other expenses	37.8%	63	46	61	43	49	37
Total Expenses	15.6%	223	193	224	180	187	189
Profit Before exceptional items and Tax	4.8%	45	43	41	63	23	36
Exceptional items before tax	72.4%	0.03	-2.51	0	0	0	0
Total profit before tax	10%	45	41	41	63	23	36
Current tax	35.7%	20	15	14	20	5.9	14
Deferred tax	-2400%	-11.88	1.56	-2.27	-1.75	0.89	-3.14
Total tax	-53.7%	7.95	16	12	19	6.79	11
Total profit (loss) for period	50%	37	25	29	44	17	26
Other comp. income net of taxes	-232.8%	-2.4	3.56	-4.98	5.85	-0.49	-0.09
Total Comprehensive Income	25.9%	35	28	24	50	16	26
Earnings Per Share, Basic	97.5%	3.37	2.2	2.58	4.08	1.47	2.27
Earnings Per Share, Diluted	100%	3.28	2.14	2.54	4.04	1.46	2.27
Debt equity ratio	-	-	-	-	005	0.065	008
Debt service coverage ratio	-	-	-	-	0.0621	0.0211	0.0339
Interest service coverage ratio	-	-	-	-	0.1253	0.2023	0.3077

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	9.5%	730	667	605	598	636	466
Other Income	22.9%	44	36	34	51	33	18
Total Income	10.1%	774	703	639	649	669	483
Cost of Materials	6.2%	360	339	306	294	351	216
Purchases of stock-in-trade	-	7.79	0	0	0	2.01	46
Employee Expense	23.5%	122	99	83	73	65	59
Finance costs	79.2%	11	6.58	5.81	10	4.32	4.19
Depreciation and Amortization	15.4%	31	27	24	15	14	14
Other expenses	1.6%	132	130	116	121	118	62
Total Expenses	4.8%	638	609	528	533	545	392
Profit Before exceptional items and Tax	45.2%	136	94	111	116	124	91
Exceptional items before tax	-	-2.16	0	-41.09	0	2.75	0
Total profit before tax	41.9%	133	94	70	116	126	91
Current tax	44.8%	43	30	27	34	33	23
Deferred tax	-20%	-5.95	-4.79	-7.55	-4.21	0.77	1.17
Total tax	50%	37	25	20	30	34	24
Total profit (loss) for period	41.2%	97	69	51	85	93	68
Other comp. income net of taxes	24.4%	-0.18	-0.56	-0.15	-0.67	0.3	0.52
Total Comprehensive Income	43.3%	97	68	50	85	93	68
Earnings Per Share, Basic	46.9%	9.17	6.56	4.85	8.234	8.97	6.54
Earnings Per Share, Diluted	45.5%	9	6.5	4.77	8.104	8.81	6.4
Debt equity ratio	-	-	005	007	008	01	0
Debt service coverage ratio	-	-	0.028	0.0286	0.0679	0.044	0
Interest service coverage ratio	-	-	0.153	0.235	0.1293	-	0

Description	(%) Q/Q	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024
Revenue From Operations	28.7%	212	165	190	163	156	180
Other Income	-7.8%	9.3	10	26	11	9.36	12
Total Income	26.4%	221	175	216	174	165	191
Cost of Materials	29.5%	102	79	90	89	69	88
Purchases of stock-in-trade	-	7.79	0	0	0	0	0
Employee Expense	0%	32	32	30	28	25	26
Finance costs	68.8%	1.81	1.48	2.71	5.11	1.3	0.67
Depreciation and Amortization	0.6%	7.84	7.8	7.69	7.68	7.43	6.96
Other expenses	37%	38	28	47	31	39	31
Total Expenses	20.5%	177	147	183	143	151	161
Profit Before exceptional items and Tax	59.3%	44	28	33	31	14	30
Exceptional items before tax	81.8%	0.36	-2.51	0	0	0	0
Total profit before tax	79.2%	44	25	33	31	14	30
Current tax	53.4%	11	7.52	11	13	3.95	10
Deferred tax	82.6%	0.68	-0.84	-2.75	-3.04	-1.04	-1.55
Total tax	93.7%	12	6.68	8.66	9.51	2.9	8.72
Total profit (loss) for period	72.2%	32	19	25	21	11	21
Other comp. income net of taxes	18.8%	0.05	-0.17	0.04	-0.1	-0.14	-0.12
Total Comprehensive Income	82.4%	32	18	25	21	11	21
Earnings Per Share, Basic	171.1%	3.06	1.76	2.35	2	1.08	2
Earnings Per Share, Diluted	176.4%	2.99	1.72	2.31	1.98	1.07	2
Debt equity ratio	-	-	-	-	004	005	006
Debt service coverage ratio	-	-	-	-	0.036	0.0201	0.03
Interest service coverage ratio	-	-	-	-	0.0697	0.1205	0.4554

Category	BLISSGVS	Pharmaceuticals
PE	38.43	37.17
PS	4.91	5.10
Growth	19.6 %	10.7 %

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	21.4%	35	29	24	33	23	42
Current investments	-88.8%	1.45	5.01	0	0	0.56	0.97
Loans, current	1%	0.04	0.03	0.04	0.05	0.07	0.05
Total current financial assets	1%	744	737	661	661	632	549
Inventories	27.1%	151	119	126	131	118	125
Current tax assets	-	0	0	3.12	2.92	2.91	1.35
Total current assets	6.3%	946	890	819	851	812	747
Property, plant and equipment	17.8%	451	383	397	356	362	371
Capital work-in-progress	-86.7%	6.05	39	21	24	7.83	1.82
Investment property	0%	0.68	0.68	0.68	0.68	0.68	0.69
Goodwill	0%	7.71	7.71	7.71	7.71	7.71	7.71
Non-current investments	-35.7%	3.52	4.92	4.38	4.34	3.61	2.88
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	17.8%	54	46	36	20	12	55
Total non-current assets	7.1%	546	510	474	431	402	451
Total assets	6.6%	1,492	1,400	1,301	1,283	1,214	1,197
Borrowings, non-current	-108.3%	0	13	20	28	36	46
Total non-current financial liabilities	-27.6%	22	30	33	36	45	57
Provisions, non-current	119.1%	3.41	2.1	4.36	3.37	2.54	1.9
Total non-current liabilities	-22.6%	25	32	37	42	51	62
Borrowings, current	-91.2%	2.93	23	51	55	52	40
Total current financial liabilities	12.5%	190	169	158	183	149	154
Provisions, current	85.6%	4.75	3.02	0.64	0.76	0	3.44
Current tax liabilities	52.6%	30	20	3.77	2.45	1.87	3.16
Total current liabilities	18.1%	236	200	172	193	160	172
Total liabilities	12.6%	261	232	209	234	211	234
Equity share capital	0%	11	11	11	11	10	10
Non controlling interest	8.6%	39	36	41	38	36	33
Total equity	5.5%	1,232	1,168	1,092	1,048	1,003	963
Total equity and liabilities	6.6%	1,492	1,400	1,301	1,283	1,214	1,197

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	-84.5%	3.33	16	6.83	15	14	26
Current investments	-124.9%	0	5.01	0	0	0	0
Loans, current	-3.4%	29	30	37	36	36	87
Total current financial assets	-3.3%	669	692	656	651	625	613
Inventories	26.4%	111	88	82	98	89	98
Current tax assets	-	0	0	2.39	2.44	2.45	0.83
Total current assets	1.9%	826	811	768	805	773	764
Property, plant and equipment	17.1%	419	358	368	325	330	334
Capital work-in-progress	-91.1%	4.4	39	21	24	7.83	1.82
Investment property	0%	0.68	0.68	0.68	0.68	0.68	0.69
Non-current investments	0%	19	19	19	19	19	18
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	19.6%	68	57	42	33	25	61
Total non-current assets	4.7%	518	495	452	412	380	411
Total assets	2.9%	1,344	1,306	1,220	1,217	1,153	1,175
Borrowings, non-current	-108.3%	0	13	20	28	35	46
Total non-current financial liabilities	-42.9%	17	29	32	36	44	56
Provisions, non-current	104.1%	3	1.98	4.36	3.33	2.47	1.82
Total non-current liabilities	-36.7%	20	31	37	39	47	63
Borrowings, current	-104.5%	0	23	31	34	31	16
Total current financial liabilities	-2.6%	151	155	119	148	110	122
Provisions, current	82.7%	4.69	3.02	0.49	0.76	0	0
Current tax liabilities	-52.4%	4.03	7.36	0	0.48	0.54	2.69
Total current liabilities	-1.2%	169	171	125	153	117	134
Total liabilities	-6.5%	189	202	161	193	164	197
Equity share capital	0%	11	11	11	11	10	10
Total equity	4.6%	1,155	1,104	1,059	1,024	988	978
Total equity and liabilities	2.9%	1,344	1,306	1,220	1,217	1,153	1,175

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	54.5%	12	8.12	6.91	10	4.74	-
Change in inventories	-47.9%	-45.5	-30.45	-22.42	15	-29.1	-
Depreciation	14.3%	33	29	26	19	17	-
Impairment loss / reversal	-	0	0	29	0	0	-
Unrealised forex losses/gains	-282.1%	-23.19	-5.33	-22.65	3	-3.88	-
Adjustments for interest income	14.3%	17	15	12	7.5	8.82	-
Share-based payments	142.7%	8.62	4.14	3.82	3.9	5.71	-
Net Cashflows from Operations	26.8%	181	143	187	79	169	-
Interest paid	-	0	0	0	0	34	-
Income taxes paid (refund)	13.9%	42	37	35	45	0	-
Other inflows (outflows) of cash	-	-0.64	0	0	0	0	-
Net Cashflows From Operating Activities	31.4%	139	106	152	34	135	-
Cash payment for investment in partnership firm or association of persons or LLP	-	0	0	0	0	74	-
Proceeds from sales of PPE	-36.1%	2.54	3.41	0.6	0.69	1.07	-
Purchase of property, plant and equipment	-25.3%	57	76	28	94	0	-
Purchase of intangible assets	-28.2%	0	0.22	0	0	0	-
Purchase of other long-term assets	-	52	0	0	0	0	-
Interest received	6.7%	17	16	5.01	13	5.89	-
Other inflows (outflows) of cash	310%	43	-19	-110.1	78	-25.93	-
Net Cashflows From Investing Activities	48.6%	-38.28	-75.44	-132.82	-7.75	-92.98	-
Proceeds from issuing shares	-57.7%	1.8	2.89	2.31	2.04	2.28	-
Proceeds from exercise of stock options	-	0	0	0.04	0	0	-
Proceeds from borrowings	-94%	4.25	55	15	40	11	-
Repayments of borrowings	-11.3%	64	72	24	54	26	-
Payments of lease liabilities	15.2%	5.02	4.49	2.85	1.37	2.12	-
Dividends paid	124.7%	11	5.45	5.39	5.44	5.33	-
Interest paid	140.5%	15	6.82	6.1	6.3	2.96	-
Other inflows (outflows) of cash	-	-0.2	0	0	0	0	-
Net Cashflows from Financing Activities	-187.8%	-89.21	-30.34	-20.89	-24.94	-23.73	-
Effect of exchange rate on cash eq.	0%	0.1	0.1	-0.15	1.4	0	-
Net change in cash and cash eq.	1398.7%	11	0.23	-1.42	3.02	19	-

BLISSGVS - Bliss GVS Pharma Limited Share Price

BLISSGVS

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

BLISSGVS - Bliss GVS Pharma Limited Share Price

BLISSGVS

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

BLISSGVS

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Bliss GVS Pharma Limited do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

BLISSGVS

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Bliss GVS Pharma Limited do?

Important Disclosure & Data Context